A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with relapsing-remitting or secondary progressive multiple sclerosis

Multiple Sclerosis Journal

Volumn 17, Issue 2, 2011, Pages 181-191

  Vollmer, Timothy L ^a   Wynn, Daniel R ^b   Alam, Shamsul M ^c   Valdes, Joaquin ^c  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b Consultants in Neurology Ltd Multiple Sclerosis Center ^*  (United States)

^c ABBOTT LABORATORIES   (United States)

Author keywords

ABT 874; IL 12; IL 23; multiple sclerosis; relapsing remitting; secondary progressive

Indexed keywords

AMYLASE; BRIAKINUMAB; CALCIUM; GADOLINIUM; PLACEBO;

ABDOMINAL PAIN; ABNORMAL SENSATION; ADULT; ALLERGIC RHINITIS; AMYLASE BLOOD LEVEL; ANXIETY; ARTERY OCCLUSION; ARTHRALGIA; ARTHRITIS; ARTICLE; BACKACHE; BIPOLAR DISORDER; BREAST HYPERTROPHY; CALCIUM BLOOD LEVEL; CONSTIPATION; CONTRAST ENHANCEMENT; CONTUSION; CORONARY ARTERY OBSTRUCTION; COUGHING; DEPRESSION; DIARRHEA; DISABILITY; DISEASE COURSE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG INDUCED CANCER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; ERYTHEMA; ESOPHAGITIS; EXPANDED DISABILITY STATUS SCALE; FALLING; FATIGUE; FEMALE; GAIT DISORDER; HEART ATRIUM FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HEPATITIS; HUMAN; HYPERCOAGULABILITY; HYPERGLYCEMIA; HYPESTHESIA; HYPOGLYCEMIA; INFECTION; INFLUENZA; INJECTION SITE CONTUSION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE RASH; INJECTION SITE REACTION; INSOMNIA; INTERVERTEBRAL DISK DEGENERATION; LIMB PAIN; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS FUNCTIONAL COMPOSITE; MUSCLE SPASM; MUSCLE WEAKNESS; MUSCULOSKELETAL STIFFNESS; MYALGIA; NAUSEA; NECK PAIN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPOROSIS; OTALGIA; PAIN; PARESTHESIA; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RELAPSE; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; SYNCOPE; TERATOMA; THORAX PAIN; TREATMENT DURATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VALVULAR HEART DISEASE;

EID: 79951524055     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458510384496     Document Type: Article

References (24)

1. National Multiple Sclerosis Society. Who gets MS? http://www. nationalmssociety.org2010.
2. Aranami T. and Yamamura T. Th17 Cells and autoimmune encephalomyelitis (EAE/MS). Allergol Int 2008 ; 2: 115-120. (Pubitemid 351897665)
3. Vandenbroeck K., Alloza I., Gadina M. and Matthys P. Inhibiting cytokines of the interleukin-12 family: recent advances and novel challenges. J Pharm Pharmacol 2004 ; 2: 145-160. (Pubitemid 38232744)
4. Kang BY and Kim TS Targeting cytokines of the interleukin-12 family in autoimmunity. Curr Med Chem 2006 ; 10: 1149-1156.
5. Oppmann B., Lesley R., Blom B., Timans JC, Xu Y., Hunte B., et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000 ; 5: 715-725.
6. Aggarwal S., Ghilardi N., Xie MH, de Sauvage FJ and Gurney AL Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003 ; 3: 1910-1914. (Pubitemid 36801431)
7. Cooke A. Th17 cells in inflammatory conditions. Rev Diabet Stud 2006 ; 2: 72-75.
8. Gately MK, Renzetti LM, Magram J., Stern AS, Adorini L., Gubler U., et al. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol 1998 ; 495-521. (Pubitemid 28183374)
9. Mosmann TR and Coffman RL TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989 ; 145-173. (Pubitemid 19138011)
10. Sospedra M. and Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005 ; 683-747. (Pubitemid 40563183)
11. Kebir H., Kreymborg K., Ifergan I., Dodelet-Devillers A., Cayrol R., Bernard M., et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med 2007 ; 10: 1173-1175. (Pubitemid 47530640)
12. Langrish CL, Chen Y., Blumenschein WM, Mattson J., Basham B., Sedgwick JD, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005 ; 2: 233-240. (Pubitemid 40189432)
13. Segal BM and Shevach EM IL-12 unmasks latent autoimmune disease in resistant mice. J Exp Med 1996 ; 2: 771-775. (Pubitemid 26324133)
14. Brok HP, van Meurs M., Blezer E., Schantz A., Peritt D., Treacy G., et al. Prevention of experimental autoimmune encephalomyelitis in common marmosets using an anti-IL-12p40 monoclonal antibody. J Immunol 2002 ; 11: 6554-6563. (Pubitemid 36903508)
15. Hart BAT, Brok HP, Remarque E., Benson J., Treacy G., Amor S., et al. Suppression of ongoing disease in a nonhuman primate model of multiple sclerosis by a human-anti-human IL-12p40 antibody. J Immunol 2005 ; 7: 4761-4768.
16. Kasper LH, Everitt D., Leist TP, Ryan KA, Mascelli MA, Johnson K., et al. A phase I trial of an interleukin-12/23 monoclonal antibody in relapsing multiple sclerosis. Curr Med Res Opin 2006 ; 9: 1671-1678. (Pubitemid 44449223)
17. McDonald WI, Compston A., Edan G., Goodkin D., Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001 ; 1: 121-127.
18. Segal BM, Constantinescu CS, Raychaudhuri A., Kim L., Fidelus-Gort R. and Kasper LH Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol 2008 ; 9: 796-804.
19. Paulson SK, Hrusk M., Valdes J. and Awni W. The pharmacokinetics of a fully human interleukin-12/23 monoclonal antibody (ABT 874) in normal healthy volunteers. In: (ed.) Proceedings from the 17th Congress of European Academy of Dermatology and Venereology, 17-21 September 2008, Paris, France. J Am Academy of Dermatology 2009 ; 60; suppl1: AB168, DOI: 10.016/ j.jaad.2008.11.732, abstract 1389.
20. Stelara (package insert). Centocor Ortho Biotech Inc., Horsham, PA, USA, 2009.
21. Longbrake EE and Racke MK Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis ? Expert Rev Neurother 2009 ; 3: 319-321.
22. Thakker P., Leach MW, Kuang W., Benoit SE, Leonard JP and Marusic S. IL-23 is critical in the induction but not in the effector phase of experimental autoimmune encephalomyelitis. J Immunol 2007 ; 4: 2589-2598. (Pubitemid 46233462)
23. Kappos L., Antel J., Comi G., Montalban X., O'Connor P., Polman CH, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006 ; 11: 1124-1140. (Pubitemid 44394919)
24. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003 ; 1: 15-23. (Pubitemid 36026342)